本帖最后由 老马 于 2013-3-13 13:43 编辑
9 S/ {. `. N1 V+ J" D
$ f+ A H0 r; w( ` t+ \健择(吉西他滨)+顺铂+阿瓦斯汀
2 h& x! K' L6 }# k! ~. ^1 c) T Gemzar +Cisplatin + Avastin9 @& a/ s9 |8 ^* M6 q- ^$ _
http://annonc.oxfordjournals.org/content/21/9/1804.full5 D- @1 |& R/ O( X
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) % ?: |2 v/ \7 i% f" P4 ]4 j; d
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. - \8 O" Q" g1 l# Y0 a* S$ |
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 7 h# i0 ^% v, J6 v5 |* g
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 910)
3 d z7 w; d6 z- G华为网盘附件:
9 F/ J# l* |% [2 c, ^' |) }0 }【华为网盘】ava.JPG
/ n% \1 Y7 q; F2 _ |